Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Enrollment complete in phase 3 study of Evamist for treating menopausal symptoms
November 17th, 2005
Vivus Inc. (VVUS) announced it completed enrollment in its pivotal phase 3 clinical study of its investigational drug Evamist (estradiol MDTS), an estradiol spray for the treatment of vasomotor symptoms associated with menopause. The MDTS system is a patented new-generation, transdermal drug delivery technology that delivers drugs through the skin. This phase 3 trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Evamist. The primary endpoint is the reduction in the frequency and severity of moderate-to-severe vasomotor symptoms associated with menopause at weeks 4 and 12 of the study....
Source: Women's Health Weekly (2005-11-17)
|
